🔍

CARERATING - CARE Ratings

📊 NSE: CARERATING 🏢 Miscellaneous 📅 Last Updated: 12/13/2025 20:43

📢 Recent Corporate Announcements

CARE Ratings Subsidiary Receives ESG Rating License from IFSCA

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 12 Mar 2026, 01:04 PM

CARE Ratings' wholly-owned subsidiary, CareEdge Global IFSC Limited, has successfully obtained a license from the International Financial Services Centres Authority (IFSCA) on March 11, 2026. This license permits the subsidiary to operate as an ESG Rating and Data Product Provider within the International Financial Services Centre. This strategic move allows the company to enter the rapidly growing global market for Environmental, Social, and Governance (ESG) assessments. The expansion diversifies the company's revenue streams beyond traditional credit rating services.

Wholly-owned subsidiary CareEdge Global IFSC Limited received the IFSCA license on March 11, 2026.
Authorized to function as an ESG Rating and Data Product Provider in the IFSC.
Positions CARE Ratings to capture demand in the specialized global ESG services market.
The license represents a regulatory milestone for the company's international service offerings.

💡 Investors should view this as a positive long-term growth driver that diversifies the company's portfolio. Monitor the scale of operations and revenue contribution from this new ESG vertical in future earnings reports.

CARE Ratings Allots 1,650 Equity Shares Under ESOP Scheme 2020

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Mar 2026, 03:52 PM

CARE Ratings Limited has approved the allotment of 1,650 equity shares to employees under its Employee Stock Option Scheme 2020. The allotment was finalized by the Nomination and Remuneration Committee on March 06, 2026. This move slightly increases the company's paid-up share capital from Rs. 30,04,53,630 to Rs. 30,04,70,130. The total number of equity shares outstanding now stands at 3,00,47,013.

Allotment of 1,650 equity shares of face value Rs. 10 each
Shares issued pursuant to the CARE Employee Stock Option Scheme 2020
Paid-up share capital increased to Rs. 30,04,70,130
Total outstanding shares increased from 3,00,45,363 to 3,00,47,013

💡 No action is required as the equity dilution is negligible and represents a routine administrative exercise of employee stock options.

CARE Ratings Reschedules Analyst/Investor Meeting to March 2, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Feb 2026, 12:51 PM

CARE Ratings Limited has announced the rescheduling of its Analyst/Institutional Investor meeting originally slated for February 25, 2026. The meeting is now set to take place on Monday, March 2, 2026, at 03:00 PM IST due to unforeseen exigencies. The company clarified that the discussions will be limited to publicly available information, specifically focusing on the Q3FY26 results. The relevant Investor Presentation is already available on the company's website for stakeholder review.

Meeting rescheduled from February 25, 2026, to March 2, 2026
New meeting time confirmed for 03:00 PM IST
Discussions to be based on the Q3FY26 Investor Presentation already in the public domain
Rescheduling attributed to administrative exigencies

💡 Investors interested in management's commentary on Q3FY26 performance should update their calendars for the new date. No immediate portfolio action is required as this is a routine administrative update.

CARE Ratings Schedules Virtual Investor Meet with Unifi Capital on Feb 25, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 07:36 PM

CARE Ratings Limited has announced a virtual meeting with Unifi Capital scheduled for February 25, 2026, at 4:00 PM. The company will utilize its existing Q3FY26 Investor Presentation for the discussion. No unpublished price sensitive information is expected to be disclosed during the session. This routine disclosure complies with SEBI Listing Obligations and Disclosure Requirements and indicates ongoing institutional engagement.

Meeting with Unifi Capital scheduled for February 25, 2026, at 4:00 PM IST
The interaction will be conducted via a virtual platform
Discussion will focus on the Q3FY26 Investor Presentation and other publicly available documents
Company confirms no unpublished price sensitive information (UPSI) will be shared

💡 Investors should treat this as a routine corporate interaction. No immediate action is required, though shareholders may review the Q3FY26 presentation for insights into current performance.

CARE Ratings to Participate in IIFL 17th Entrepreneurial India Conference on Feb 25

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Feb 2026, 05:28 PM

CARE Ratings Limited has scheduled an interaction with institutional investors at the IIFL 17th Entrepreneurial India Conference 2026. The meeting is set for February 25, 2026, starting at 9:00 AM in Mumbai. The company will rely on its existing Q3FY26 Investor Presentation and other publicly available documents for discussions. This is a routine regulatory disclosure under SEBI (LODR) Regulations, 2015, aimed at maintaining transparency with the investor community.

Participation in the IIFL 17th Entrepreneurial India Conference on February 25, 2026.
Interaction session scheduled to begin at 09:00 AM in Mumbai.
Discussions will be based on the Q3FY26 Investor Presentation already available on the company website.
Company clarified that no unpublished price sensitive information (UPSI) will be shared during the meet.

💡 No immediate action is required as this is a routine investor engagement. Investors may review the Q3FY26 Investor Presentation to understand the current business trajectory and management outlook.

CARE Ratings Receives Cautionary Letter from BSE and NSE Over Incorrect ISIN Reporting

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 18 Feb 2026, 05:10 PM

CARE Ratings Limited received cautionary letters from BSE and NSE on February 17, 2026, regarding a reporting error. The company inadvertently disclosed an incorrect ISIN for one of its clients on the System Driven Disclosure platform. Management has confirmed that this administrative oversight has no impact on the company's financial or operational activities. No monetary penalties were imposed, and the exchanges have advised the company to exercise due caution in the future.

BSE and NSE issued cautionary letters to CARE Ratings on February 17, 2026
The warning pertains to reporting an incorrect ISIN for one client on the System Driven Disclosure platform
Company confirms zero impact on financial, operational, or other activities
No monetary fines or penalties were levied by the stock exchanges

💡 Investors should view this as a minor administrative error with no impact on business fundamentals. No action is required as the core operations and financials remain unaffected.

CARE Ratings Schedules Meetings with SBI MF and ICICI Pru MF on February 19, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 03:43 PM

CARE Ratings Limited has announced a series of in-person meetings with prominent institutional investors scheduled for February 19, 2026. The company will meet representatives from SBI Mutual Fund at 11:30 AM, ICICI Prudential Mutual Fund at 12:30 PM, and Totem Point Management at 02:30 PM. These interactions are expected to revolve around the company's Q3FY26 performance and strategic outlook. The discussions will be strictly based on publicly available information and the latest investor presentation.

In-person meetings scheduled with 3 major institutional investors on Feb 19, 2026
Key participants include SBI Mutual Fund and ICICI Prudential Mutual Fund
Meetings are timed at 11:30 AM, 12:30 PM, and 02:30 PM respectively
Discussions to focus on Q3FY26 results and publicly available data

💡 This is a routine disclosure; investors should keep an eye on any subsequent transcripts for management commentary on growth prospects.

CARE Ratings Reports Strong Q3 FY26 Performance with 24% YoY Growth in Consolidated PAT

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:40 PM

CARE Ratings Limited reported a robust performance for 9M FY26, with consolidated revenue from operations growing 17% YoY to Rs. 342.40 crore. Profitability saw a significant jump as consolidated PAT rose 24% YoY to Rs. 120.25 crore, driven by operational efficiencies and a 46% standalone EBITDA margin. While the ratings segment remains the core contributor at 89% of revenue, the non-ratings segment showed faster growth at 21% YoY. Despite a 11% decline in corporate bond issuances during Q3, the company benefited from a 14.5% increase in bank credit offtake.

Consolidated PAT for 9M FY26 grew by 24% YoY to Rs. 120.25 crore with a 32% margin.
Consolidated revenue from operations for 9M FY26 increased 17% YoY to Rs. 342.40 crore.
Standalone EBITDA margin stood at a healthy 46% for 9M FY26, up from 44% in the previous year.
Non-ratings segment revenue grew by 21% YoY to Rs. 36.71 crore, contributing 11% to total revenue.
Bank credit offtake accelerated to 14.5% growth as of December 2025, supporting rating volumes.

💡 Investors should view the strong margin expansion and growth in non-rating segments as positive indicators of business diversification and efficiency. The stock remains a play on the Indian credit cycle and private capex revival, though moderation in bond issuances is a factor to watch.

CARE Ratings Q3 Net Profit Jumps 29% YoY to ₹35.9 Crore; Revenue Up 16%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:19 PM

CARE Ratings reported a strong year-on-year performance for the quarter ended December 31, 2025, with consolidated net profit rising 29.1% to ₹35.9 crore. Revenue from operations grew by 16.3% YoY to ₹112.1 crore, reflecting steady demand in the credit rating and analytics business. While sequential performance showed a decline from the September quarter, the nine-month (9M FY26) net profit remains robust at ₹118.3 crore, a 25% increase over the previous year. The company continues to manage its cost base effectively despite a rise in employee benefit expenses.

Consolidated Revenue from operations increased 16.3% YoY to ₹112.12 crore in Q3 FY26.
Net Profit attributable to owners grew 29.1% YoY to ₹35.90 crore from ₹27.80 crore.
9M FY26 Net Profit reached ₹118.34 crore, up 25% compared to ₹94.63 crore in 9M FY25.
Total expenses for the quarter rose to ₹76.12 crore, with employee costs accounting for ₹55.13 crore.
Other income remained a significant contributor at ₹12.99 crore for the quarter.

💡 Investors should view the strong year-on-year growth as a positive indicator of the company's market position. The stock remains a key beneficiary of the expanding Indian corporate bond market and credit growth.

CARE Ratings Q3 FY26 Net Profit Jumps 29% YoY to ₹35.9 Crore

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:05 PM

CARE Ratings Limited reported a robust year-on-year performance for the quarter ended December 31, 2025 (Q3 FY26), with consolidated revenue from operations rising 16.3% to ₹112.12 crore. Net profit attributable to owners saw a significant jump of 29.1% YoY, reaching ₹35.90 crore. While sequential (QoQ) performance showed a decline in both revenue and profit, the nine-month (9M FY26) figures remain strong with a 25% growth in net profit to ₹118.34 crore. The company maintains healthy margins despite a rise in employee benefit expenses.

Consolidated Revenue from operations increased 16.3% YoY to ₹112.12 crore from ₹96.38 crore.
Net Profit for the quarter rose 29.1% YoY to ₹35.90 crore, up from ₹27.80 crore in Q3 FY25.
9M FY26 total income reached ₹381.51 crore compared to ₹328.25 crore in 9M FY25.
Employee benefit expenses increased to ₹55.13 crore in Q3 FY26 from ₹50.33 crore YoY.
Consolidated Profit Before Tax (PBT) for the quarter stood at ₹48.99 crore.

💡 The strong YoY growth and 9-month performance indicate solid business momentum and improved operational efficiency. Investors should view the sequential dip as seasonal and focus on the company's improving annual profitability and market position.

CARE Ratings Allots 3,500 Equity Shares Under ESOP Scheme 2020

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Feb 2026, 05:52 PM

CARE Ratings Limited has approved the allotment of 3,500 equity shares to employees following the exercise of options under its 2020 ESOP scheme. This action increases the company's total paid-up share capital from Rs. 30.041 crore to Rs. 30.045 crore. The total number of outstanding equity shares now stands at 3,00,45,363. This is a routine administrative update with negligible impact on existing shareholder value.

Allotment of 3,500 equity shares of face value Rs. 10 each
Shares issued pursuant to the CARE Employee Stock Option Scheme 2020
Paid-up share capital increased to Rs. 30,04,53,630
Total outstanding shares increased from 3,00,41,863 to 3,00,45,363

💡 No action is required as the equity dilution is extremely minimal (approximately 0.01%). Investors should remain focused on the company's operational performance and market share in the credit rating industry.

CARE Ratings Announces Resignation of Non-Executive Director Sobhag Mal Jain

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 27 Jan 2026, 06:19 PM

Mr. Sobhag Mal Jain has resigned from his position as a Non-Executive Non-Independent Director at CARE Ratings Limited, effective January 27, 2026. The resignation is attributed to his preoccupation and other professional commitments. This change is part of routine board movements and does not involve an executive role. The company will need to follow regulatory formalities to record this cessation. Investors should note that this is a non-executive departure and is unlikely to impact daily operations.

Mr. Sobhag Mal Jain resigned as Non-Executive Non-Independent Director effective January 27, 2026.
The reason for resignation is cited as preoccupation and other professional commitments.
The resignation was submitted via a letter dated January 27, 2026.
The company is in the process of completing necessary regulatory filings for the cessation.

💡 This is a routine administrative change involving a non-executive director; no immediate action is required. Monitor for any future board appointments to ensure continued governance standards.

CARE Ratings Announces Revised Composition of Board Committees

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 20 Jan 2026, 04:25 PM

CARE Ratings Limited has announced a reorganization of its Board Committees following a meeting held on January 20, 2026. The restructuring involves three primary committees: Nomination and Remuneration, Stakeholders Relationship, and Strategy and Investment. Key appointments include Mr. Manoj Chugh, Ms. Indrani Banerjee, and Mr. Rajiv Bansal as chairpersons for their respective committees. These changes are effective immediately as of the board meeting date. This update is part of the company's routine compliance with SEBI Listing Obligations and Disclosure Requirements.

Reconstitution of 3 key board committees approved on January 20, 2026
Appointment of 3 new chairpersons for the Nomination, Stakeholders, and Strategy committees
The Strategy and Investment Committee now comprises 5 members including Mr. Rajiv Bansal as Chair
The Nomination and Remuneration Committee consists of 4 members under Mr. Manoj Chugh

💡 This is a routine governance update with no direct impact on financial performance. Investors should maintain their current positions as this does not change the company's fundamental outlook.

CARE Ratings Shareholders Approve Dr. Bimal Patel as Independent Director with 99.98% Votes

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 16 Jan 2026, 03:30 PM

CARE Ratings Limited has successfully passed a special resolution for the appointment of Dr. Bimal Patel as a Non-Executive Independent Director. The voting, conducted through a postal ballot ending January 15, 2026, saw a total of 13,129,545 votes polled. The resolution received near-unanimous support, with 99.98% of the votes cast in favor. Institutional investors were particularly supportive, casting 100% of their 11.67 million votes in favor of the appointment.

Appointment of Dr. Bimal Patel as Non-Executive Independent Director approved via special resolution
99.98% of total votes (13,127,587) were cast in favor of the resolution
Institutional participation was strong with 11,668,962 votes, all 100% in favor
Total voting turnout represented 43.75% of the company's total 30,013,363 shares

💡 No immediate action is required as this is a routine board appointment. Investors may view the high level of institutional support as a positive sign of stable corporate governance.

CARE Ratings Allots 16,834 Equity Shares Under ESOP Scheme 2020

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Jan 2026, 10:24 AM

CARE Ratings Limited has approved the allotment of 16,834 equity shares to employees following the exercise of options under the CARE Employee Stock Option Scheme 2020. The allotment was finalized by the Nomination and Remuneration Committee on January 09, 2026. This action increases the company's paid-up share capital from Rs. 30.02 crore to approximately Rs. 30.04 crore. The total number of outstanding equity shares has risen to 3,00,41,863 shares of Rs. 10 each.

Allotment of 16,834 equity shares of face value Rs. 10 each under ESOP 2020.
Paid-up share capital increased from Rs. 30,02,50,290 to Rs. 30,04,18,630.
Total equity shares outstanding increased to 3,00,41,863 from 3,00,25,029.
The equity dilution resulting from this allotment is approximately 0.056%.

💡 No action is required as this is a routine administrative allotment with negligible impact on earnings per share or ownership structure.

View All CARERATING Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Ratings business revenue grew 16% YoY to Rs. 205.75 Cr in H1 FY26, while the non-ratings segment recorded a strong 30% YoY growth to Rs. 24.53 Cr. For FY2025, consolidated revenue from operations reached Rs. 402.32 Cr, a 21.30% increase from Rs. 331.68 Cr in FY2024.

Geographic Revenue Split

Primarily India-focused, though the company is expanding its global footprint through 'CareEdge Global' with strategic MOUs in regions like Mauritius. Specific percentage splits by region are not disclosed in available documents.

Profitability Margins

Consolidated PAT margin stood at 33% in H1 FY26 (Rs. 83.71 Cr), while Standalone PAT margin was 39% (Rs. 84.95 Cr). For FY2025, consolidated PAT margin was 34.8% (Rs. 140.01 Cr), up from 30.9% in FY2024.

EBITDA Margin

Consolidated EBITDA margin was 42% in H1 FY26 (Rs. 96.30 Cr), up 24% YoY. Standalone EBITDA margin reached 57% in Q2 FY26 (Rs. 64.97 Cr), reflecting high operational efficiency in core rating services.

Capital Expenditure

Net Block of assets stood at Rs. 119.21 Cr as of March 31, 2025, representing a 10% increase from Rs. 108.82 Cr in FY2024, driven by investments in technology and infrastructure.

Credit Rating & Borrowing

Not disclosed as the company appears to be debt-free; Debt-Equity and Interest Coverage ratios are listed as Not Applicable (NA) in standalone financial summaries.

⚙️ Operational Drivers

Raw Materials

As a service-based agency, the primary 'raw material' is human capital; employee costs represent 46.9% of total revenue (Rs. 188.92 Cr in FY2025).

Key Suppliers

Not applicable; the business relies on professional analysts and technological infrastructure rather than physical raw material suppliers.

Capacity Expansion

Not applicable in MT/MW; however, the company is expanding its 'rating universe' and geographical reach, resulting in an increase in new rating market share by count in FY2025.

Raw Material Costs

Employee costs, the primary operational expense, grew 14.79% YoY to Rs. 188.92 Cr in FY2025, reflecting investments in talent retention and skill upgrading.

Manufacturing Efficiency

Manufacturing efficiency is not applicable; however, debtors turnover ratio was 12.54x in FY2025, and the company is upgrading ML models to improve data extraction efficiency.

📈 Strategic Growth

Expected Growth Rate

17-21%

Growth Strategy

Growth will be achieved by diversifying into non-rating segments (Analytics, Consulting, Sustainability) which now contribute 11% to revenue, and by capitalising on new SEBI mandates such as monitoring equity issuance proceeds. The company is also expanding globally via CareEdge Global and focusing on high-growth sectors like Infrastructure and BFSI.

Products & Services

Credit ratings for corporate bonds, commercial papers, and bank loans; Integrated Credit Platform (ICP) for risk analytics; ESG and sustainability assessments; Monitoring of equity issuance proceeds.

Brand Portfolio

CareEdge, CareEdge Ratings, CareEdge Global, CareEdge Analytics, CareEdge Advisory.

New Products/Services

Monitoring of equity issuance proceeds (market leader) and Past Risk and Return Verification Agency services (SEBI approved).

Market Expansion

Expanding into the International Financial Services Centre (GIFT City) and global markets like Mauritius.

Market Share & Ranking

Leading credit rating agency in India with a leadership position in Infrastructure and BFSI segments; securitisation volumes grew 55% in FY2025.

Strategic Alliances

Strategic MOUs with entities like the Mauritius Chamber of Commerce and Industry to drive global growth.

🌍 External Factors

Industry Trends

The industry is evolving toward integrated risk solutions and data analytics. Regulatory shifts, such as SEBI's 'Ease of doing business' initiatives and cyber security frameworks, are redefining operational standards.

Competitive Landscape

Operates in a regulated oligopoly; maintains leadership in Infrastructure and BFSI while facing competition from other domestic rating agencies.

Competitive Moat

Moat is sustained by mandatory regulatory requirements (SEBI/RBI accreditation) and high switching costs due to reputation. CareEdge's leadership in Infrastructure and high stability ratios provide a durable competitive advantage.

Macro Economic Sensitivity

Highly sensitive to GDP growth and private investment cycles; muted private investment in FY2025 impacted the core rating business growth momentum.

Consumer Behavior

Corporates are increasingly using commercial papers (issuances up 18.5% in H1 FY26) as a flexible funding tool compared to long-term bonds during yield volatility.

Geopolitical Risks

Global economic volatility and US reciprocal tariffs are identified as external headwinds that could impact domestic demand and corporate fundraising.

⚖️ Regulatory & Governance

Industry Regulations

Regulated by SEBI (CRA Regulations) and RBI (Basel-III framework). New mandates include monitoring equity issuance proceeds and adhering to the SEBI 'Cyber security and resilience framework' (2025).

Environmental Compliance

Not disclosed; service industry has low direct environmental impact.

Taxation Policy Impact

Effective tax rate of 27.1% in FY2025, with total tax expenses of Rs. 52.26 Cr on a PBT of Rs. 192.27 Cr.

⚠️ Risk Analysis

Key Uncertainties

Potential implementation of the Internal Rating Based (IRB) approach by RBI could make external ratings non-mandatory for some banks, impacting 89% of the company's revenue stream.